KCNQ4抗体;KCNQ4 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human fetal brain tissue, mouse brain tissue, Primary antibody: P11880(KCNQ4 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 7 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11880(KCNQ4 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P11880(KCNQ4 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The KCNQ4 antibody is a research tool designed to detect and study the KCNQ4 protein, a voltage-gated potassium channel subunit encoded by the *KCNQ4* gene. As a member of the Kv7 (KCNQ) family, KCNQ4 plays a critical role in regulating neuronal excitability and auditory function. It is predominantly expressed in the central nervous system, cochlear hair cells, and smooth muscle cells, where it contributes to the maintenance of resting membrane potential and signal transduction. Mutations in *KCNQ4* are linked to autosomal dominant hearing loss (DFNA2) and neurological disorders, underscoring its physiological importance.

KCNQ4 antibodies are widely used in biomedical research to investigate the protein’s expression, localization, and functional interactions. They enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence to visualize KCNQ4 distribution in tissues or cultured cells. These antibodies also aid in studying channelopathies, drug responses, and molecular mechanisms underlying diseases. For example, researchers employ them to explore how KCNQ4 dysfunction leads to hyperexcitability in neurons or hearing impairment.

Developed in various host species (e.g., rabbit, mouse), KCNQ4 antibodies are validated for specificity and sensitivity, often targeting epitopes in conserved regions like the C-terminus or pore domain. Their applications extend to screening therapeutic compounds targeting Kv7 channels for conditions like epilepsy or neuropathic pain. However, careful validation is essential to avoid cross-reactivity with homologous KCNQ subunits (e.g., KCNQ2. KCNQ3). Overall, KCNQ4 antibodies are indispensable for advancing our understanding of potassium channel biology and related pathologies.